Medtronic has entered into an agreement with EPIX Therapeutics in Santa Clara, California to acquire the company — a move that expands its presence in the fast-growing catheter ablation market.
EPIX’s main product, the DiamondTemp ablation system, is a temperature-controlled system that physicians can use for improved control and feedback during cardiac ablation procedures. It uses radiofrequency energy to make scar tissue in the heart.
The DiamondTemp system received a CE Mark in 2017 and is currently in an investigational device evaluation study in the U.S.
The acquisition is expected to become final by April 26 if all conditions are met.